Biotechnology

GRI Bio (NASDAQ: GRI), a San Diego-based biotech targeting iNKT cells for autoimmune therapies, will present its immunomodulatory platform at A.G.P.’s 2025 Healthcare Showcase on May 21 (2:40 PM ET) via live webcast. Dr. Marc Hertz, CEO, will outline advancements over traditional CAR-T approaches and highlight upcoming Phase II results for GRI-0621 (IPF/lupus pipelines) and its 500-compound library. The event attracts 500+ investors and historically correlates with 8% stock performance gains, offering critical visibility for the company’s early-inflammation intervention strategy. [99 words]

Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotech company developing Treg-targeted therapies for neuroinflammatory diseases, will headline H.C. Wainwright’s BioConnect Conference in New York City on May 16, 2025. CEO Dr. Arun Swaminathan will discuss the integration of its proprietary platforms, including lead compound COYA 302—a dual-pathway subcutaneous treatment combining LD IL-2 and CTLA4-Ig to address neuroinflammation. The company emphasizes its platforms’ potential in neurodegenerative, autoimmune, and metabolic disorders, while noting risks related to clinical timelines, regulation, and capital intensity in SEC filings. A live stream of the conference session will be available on its investor relations page for 90 days.